Intersection · Practice × tirzepatide
Practice topics tagged tirzepatide
Topics in Practice carrying the tag tirzepatide. Dual GIP and GLP-1 receptor agonist.
26 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Restarting after a long gap: what the labelling implies
Posting this under the heading it deserves: Restarting after a long gap: what the labelling implies Everything below is what sits behind that. I have read the maintained page on this and I still have a gap,…
|
+41 | 46 | 11k | 15h |
|
When a dose reduction is the correct response to a side effect
When a dose reduction is the correct response to a side effect — that is the question, and I have not found it answered plainly anywhere I have looked. A question about technique rather than about dose. I…
|
+38 | 42 | 2.7k | 19h |
|
What steady state means for the decision to escalate
What steady state means for the decision to escalate — that is the question, and I have not found it answered plainly anywhere I have looked. Reporting something rather than asking about it, in case the…
|
+31 | 35 | 2k | 1d |
|
Coming back to: Where the four-week escalation interval comes from, and what it is not
Posting this under the heading it deserves: Where the four-week escalation interval comes from, and what it is not Everything below is what sits behind that. I have read the maintained page on this and I…
|
+44 | 48 | 11k | 1d |
|
Micro-titration: a disputed topic, argued properly
Micro-titration: a disputed topic, argued properly Writing it up because I had to work it out twice and would rather nobody else did. A question about technique rather than about dose. I have been doing the…
|
+99 | 110 | 61k | 2d |
|
Stepping down deliberately, and how to do it without losing progress — what changed since
Posting this under the heading it deserves: Stepping down deliberately, and how to do it without losing progress — what changed since Everything below is what sits behind that. Practical question with the…
|
+94 | 99 | 29k | 2d |
|
When a dose reduction is the correct response to a side effect — a second dataset
When a dose reduction is the correct response to a side effect — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on…
|
+10 | 14 | 42k | 2mo |
|
Restarting after a long gap: what the labelling implies — the long version
Restarting after a long gap: what the labelling implies — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
|
+12 | 17 | 2.4k | 2mo |
|
Revisiting: The arithmetic of an intermediate dose between two label steps
Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I…
|
+41 | 45 | 808 | 2mo |
|
Stepping down deliberately, and how to do it without losing progress
Stepping down deliberately, and how to do it without losing progress — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how…
|
+98 | 102 | 26k | 3mo |
|
Splitting a weekly dose in two: the pharmacokinetic argument against
Splitting a weekly dose in two: the pharmacokinetic argument against — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I…
|
+24 | 28 | 51k | 5mo |
|
Why "dose equivalence" between different incretin analogues is a weak concept
Why "dose equivalence" between different incretin analogues is a weak concept I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this…
|
+124 | 133 | 11k | 5mo |
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still have a…
|
+127 | 137 | 32k | 8mo |
|
Follow-up: The lowest dose that does anything: is that a real question?
The question in the title: The lowest dose that does anything: is that a real question? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still…
|
+70 | 75 | 12k | 8mo |
|
Dose numbers across compounds are not on the same scale
Dose numbers across compounds are not on the same scale — setting out what I have, and where I think it stops being reliable. I have read the maintained page on this and I still have a gap, so I am asking…
|
2 | 1.6k | 9mo | |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? A question about technique rather than about dose. I have been…
|
2 | 8.9k | 9mo | |
|
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept Reporting something rather than asking about it, in case the pattern…
|
+7 | 11 | 26k | 9mo |
|
Escalating every six weeks instead of four: what I observed over eight months — one year on
On the subject in the title: Escalating every six weeks instead of four: what I observed over eight months — one year on Working notes rather than a conclusion. I have read the maintained page on this and I…
|
+55 | 59 | 9.1k | 10mo |
|
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
|
+35 | 39 | 547 | 11mo |
|
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
2 | 31k | 13mo | |
|
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
|
2 | 763 | 15mo | |
|
Titrating on tolerability rather than on the calendar — the long version
Titrating on tolerability rather than on the calendar — the long version Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than asking about it, in…
|
2 | 7.7k | 17mo | |
|
Revisiting: Holding a dose indefinitely: is there a documented downside?
The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it. A question about technique rather than…
|
+26 | 30 | 4.5k | 18mo |
|
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still…
|
+131 | 147 | 47k | 18mo |
|
Follow-up: Escalating every six weeks instead of four: what I observed over eight months
Escalating every six weeks instead of four: what I observed over eight months — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have…
|
4 | 164 | 20mo | |
|
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I…
|
+56 | 60 | 21k | 2y |
Sponsored
Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing →
Sponsored
GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →